Belzutifan+pembrolizumab post-surgery helps kidney cancer patients at high risk for relapse stay cancer-free longer

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.